Ozagrel

Drug Profile

Ozagrel

Alternative Names: Cataclot; Domenan; KCT-0809; OKY 046; OXY-046 HCl; Vega; Xanbon

Latest Information Update: 07 Jun 2017

Price : $50

At a glance

  • Originator Kissei Pharmaceutical; Ono Pharmaceutical
  • Developer Kissei Pharmaceutical; Teika Pharmaceutical
  • Class Antiasthmatics; Antihistamines; Antithrombotics; Methacrylates; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane A2 synthase inhibitors; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Cerebral vasospasm; Diabetic nephropathies; Intracranial thrombosis
  • Discontinued Cerebral infarction; Cough; Dry eyes; Glomerulonephritis; Hypertension in pregnancy; Myocardial infarction; Transplant rejection

Most Recent Events

  • 26 May 2017 Kissei Pharmaceutical completes a phase III trial in Dry eyes (associated with Sjögren's Syndrome) in Japan (Ophthalmic) (NCT02503189)
  • 24 Apr 2017 Kissei Pharmaceutical terminates a phase III extension trial for Dry eyes in Japan since the results of the Phase III clinical study conducted in Japan failed to demonstrate the expected efficacy of this drug (Opthalmic) (NCT02503163)
  • 24 Apr 2017 Kissei Pharmaceutical terminates a phase III extension trial for Dry eyes in Japan since the results of the Phase III clinical study conducted in Japan failed to demonstrate the expected efficacy of this drug (Opthalmic) (NCT02503176)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top